tbuckley/cabot-search huggingface dataset:
Abstract 1193: A single phosphorylation site mutant of the Retinoblastoma protein blocks apoptosis induced by UV
Authors: Brandon Lentine, Raymond A. Hunce, Lisa Antonucci, Nancy A. Krucher
Journal: Cancer Research (2012)

Abstract The Retinoblastoma protein (Rb) is important in the control of cell proliferation and apoptosis. Its activity is controlled by reversible phosphorylation on several serine and threonine residues. When Rb is hypophosphorylated, it inhibits proliferation by preventing passage through the G1- S phase transition. Hyperphosphorylated Rb promotes cell cycle progression. The role of Rb phosphorylation in the control of apoptosis is largely unknown, although several apoptotic stimuli result in dephosphorylation of Rb. It may be the case that dephosphorylation of specific amino acids may signal apoptosis versus cell cycle arrest. Using glutamic acid mutagenesis, we have generated 15 single phosphorylation site mutants from serine/threonine to glutamic acid, to mimic the phosphorylated state. By calcium phosphate transfection mutant plasmids were introduced into C33A Rb-null cells and apoptosis was induced using UV. Apoptosis was measured by ELISA detection of degraded DNA and by immunoblotting to assess proteolytic cleavage of PARP. We found that only threonine-821 when mutated to glutamic acid blocked apoptosis by 50% whereas other sites tested had little effect. In addition, endogenous Rb is dephosphorylated on threonine-821 when cells are undergoing apoptosis. Experiments to determine the effect of this mutation in response to additional apoptotic stimuli are underway. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 1193. doi:1538-7445.AM2012-1193
ADDITION OF SPECIFIC LIPOPROTEIN(A) APHERESIS IN STABLE ISCHEMIC HEART DISEASE PATIENTS CONTRIBUTES TO CAROTID ATHEROSCLEROSIS PREVENTION
Authors: Marat V. Ezhov, Maya Safarova, Olga Afanasieva, Olga Pogorelova, Tatyana Balakhonova, Valery Kukharchuk, Sergei Pokrovsky
Journal: Journal of the American College of Cardiology (2015)
Adjuvant platinum-based chemotherapy (PBCTX) improves overall survival (OS) in women with uterine mixed Mullerian malignant tumors (MMMT)
Authors: M. Huang, B. M. Slomovitz, T. A. Caputo, R. Trocola, D. Fatemi
Journal: Journal of Clinical Oncology (2008)

16561 Background: The aim of this study was to describe clinical and pathologic characteristics of patients with MMMT of the uterus who were all treated at a single institution. In addition, we were interested in examining how these features correlated with 5 year OS. Methods: Patients diagnosed with FIGO Stage I-IV MMMT between 1993 and 2007 were identified. Clinical, pathologic and outcome data was obtained from the medical record. Median survival determinations and factors predictive of outcome were compared using the log-rank test. Results: MMMT was identified in 43 patients. The median age of diagnosis was 70 years (range 45–91). Personal history of breast cancer was present in 33% of our patients (62% with history of tamoxifen use). There were 19 stage I patients (IA - 5, IB - 10, IC - 4), 1 stage II patients, 14 stage III patients (IIIA - 4, IIIB - 3, IIIC - 7) and 9 stage IV patients. OS among all patients was 17.2% and the median OS was 36.6 months. Among the stage I patients, the OS was 36% (median - 52 months). The OS in stage III patients was 0% (median - 17 months). The OS in stage IV patients was 0% (median - 3 months). Pathologic features predictive of a worse OS included lymph vascular invasion (p=0.04), deep myometrial invasion (p=0.02), and cervical involvement (p=0.01). Within the group of patients with stage I-III disease (n=34), 47% (n=16) received adjuvant PBCTX and 59% (n=20) received whole pelvic radiation (WPRT). 29% (n=10) received combination PBCTX and WPRT. The OS for those patients who received adjuvant PBCTX was 26% (median - 51 months). The OS for stage I patients who received PBCTX was 38% (median - 52 months) and the OS for stage III patients was 0% (median - 46 months). There was a trend towards an improved survival in the stage III patients who received adjuvant chemotherapy (p=0.07). Conclusions: In our population of non-selected patients with MMMT, 33% had a personal history of breast cancer. Tamoxifen use was common among those patients with breast cancer. Stage, myometrial invasion, lymph vascular invasion, and cervical involvement were all risk factors for a worse prognosis. Adjuvant PBCTX was associated with a favorable OS in our patients. Clinical trials evaluating the role of platinum-based therapy in patients with MMMT are ongoing. No significant financial relationships to disclose.
Alpha<sub>1</sub>Fetoglobulin in the Diagnosis of Human Hepatoma
Authors: M. E. Alpert, J. Uriel, B. de Nechaud
Journal: New England Journal of Medicine (1968)

Monospecific rabbit antiserum against a human fetoglobulin was tested by double-gel diffusion against coded serums of patients with hepatoma and other liver diseases and controls in Uganda. A precipitin line indicated the presence of a human fetal alpha1 globulin in 50 per cent of the serums from 40 patients with hepatoma. The test was positive in only two of 118 patients with other forms of liver disease, including other malignant tumors metastatic to the liver, and negative in 50 hospital outpatient controls and 25 relatives of patients with hepatoma.
1064 FIBROTEST HAS NO GRAY ZONE FOR THE DIAGNOSIS OF FIBROSIS STAGES RELATIVE TO BIOPSY: THE GRAY ANATOMY OF 27869 VIRTUAL BIOPSIES AND 6500 PATIENTS
Authors: T. Poynard, G. Lenaour, J.C. Vaillant, F. Capron, M. Munteanu, D. Eyraud, Y. Ngo, H. Mkada, V. Ratziu, L. Hannoun, F. Charlotte
Journal: Journal of Hepatology (2012)
Abstract 1956: Enhanced colony-forming ability, and motility and migratory properties of Cisplatin-resistant ovarian cancer cells
Authors: Peibin Yue, Xiaolei Zhang, James Turkson
Journal: Cancer Research (2011)

Abstract Ovarian cancer causes the highest gynecologic neoplasm-related deaths in the United States. Although the majority of ovarian cancer patients respond to Cisplatin therapy, most develop recurrent and resistant disease, raising the need to understand the molecular mechanisms that support the resistant phenotype and to identify novel effective therapeutic and chemo-sensitizing modalities. In this study, we developed Cisplatin resistance in vitro to address the molecular and biological mechanisms that may be presented by the recurrent disease. The resistant lines, A2780S/CP3 and A2780S/CP5, which were derived from the Cisplatin-sensitive line, A2780S and are resistant to 3 and 5 μM Cisplatin, respectively, showed marked changes in morphology, compared to the parental cells. Notably, both resistant lines showed enhanced colony-forming ability and significantly enhanced cell motility and migratory properties. Molecular mechanistic analysis indicated the Cisplatin resistance was associated with hyperactive epidermal growth factor receptor (EGFR)-extracellular signal-regulated kinase (Erk)1/2MAPK and EGFR-Signal Transducer and Activator of Transcription (Stat)3 pathways, the overexpression of Survivin and vascular endothelial growth factor receptor (VEGF), and F-actin and Cortactin, with F-actin localization that is predominantly at the cellular extensions. Treatment of the Cisplatin-resistant A2780S/CP5 line with the EGFR inhibitor, Iressa or the Stat3 inhibitor, S3I-201 inhibited the colony-forming ability of these cells, without suppressing their viability, suggesting EGFR-Erk1/2 and EGFR-Stat3 activation are required for the proliferation of the resistant cells. Furthermore, inhibition of EGFR or Stat3 activation significantly suppresses the migration of A2780S/CP3 cells, while the motility of both A2780S/CP3 and A2780S/CP5 lines are sensitive to EGFR inhibition. These results together suggest that Cisplatin resistance in ovarian cancer is mediated in part through the activation of the EGF receptor-mediated Erk and Stat3 pathways that promote increased cell proliferation, motility and migration. These findings raise the possibility that EGFR or Stat3 inhibitors combined with Cisplatin may be an effective therapeutic approach for Cisplatin-resistant ovarian cancer. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 1956. doi:10.1158/1538-7445.AM2011-1956
716 THE EFFICACY OF A NEW QUALITATIVE SCORING SYSTEM FOR ADVANCED LIVER FIBROSIS DIAGNOSIS USING GADOXETATE DISODIUM-ENHANCED MRI IN PATIENTS WITH CHRONIC DIFFUSE LIVER DISEASES
Authors: D. Feier, C. Ballasy, N. Bastati, R. Badea, M. Trauner, A. Ba-Ssalamah
Journal: Journal of Hepatology (2013)
Detection of Saccular Coronary Artery Aneurysm Associated with Coronary–Pulmonary Artery Fistula Using Tc-99m HSAD Scintigraphy
Authors: Kenzo Sakamoto, Takahisa Sawada, Tetsuhiro Yamano, Takeshi Nakamura, Akihiro Azuma, Hiroki Sugihara, Masao Nakagawa
Journal: Clinical Nuclear Medicine (2003)

SAKAMOTO, KENZO M.D.*; SAWADA, TAKAHISA M.D.*; YAMANO, TETSUHIRO M.D.*; NAKAMURA, TAKESHI M.D.*; AZUMA, AKIHIRO M.D.*; SUGIHARA, HIROKI M.D.†; NAKAGAWA, MASAO M.D.* Author Information
Abstract ADV06: The power of social media in patient advocacy.
Authors: Annemarie Ciccarella
Journal: Cancer Research (2013)

Abstract Patient advocates are harnessing the power of social media by developing relationships with like-minded advocates from around the globe. Worldwide collaboration is now achieved seamlessly thanks to outlets like twitter with messages appended using a hash tag Of greatest interest to me is bringing the voice of the patient to every aspect along the research continuum. Our unique perspective as stakeholders whose lives are directly impacted brings invaluable input to the table. From assisting in the writing of lay abstracts for funding applications to the review of grant applications, the voice of the patient is crucial. No longer will content sit on the sidelines, advocates want to be active participants in their treatment and many of us are especially interested in playing a role in the determining what constitutes worthwhile research. If it doesn't matter to the vast majority of the patient population, is it worth pursuing? While each individual story is important, the collective voice of the community is the most important voice of all. Through social media interaction, a "connected" advocate has their finger on the pulse of what is important within their community. We sit in major conferences, sharing presentations in real time with others who are not in attendance. Active social media advocates are sharing stories as they hit the medical journals, discussing their relevance and oftentimes have doctors participating those discussions. Patients as partners, as collaborators whose voices are making a difference represent a powerful and positive paradigm shift in medical treatment and in the research landscape. Citation Format: Annemarie Ciccarella. The power of social media in patient advocacy. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr ADV06. doi:10.1158/1538-7445.AM2013-ADV06
Abstract 3619: Inhibition of FLT3 autophosphorylation and downstream signaling both in vitro and in vivo by AC220, a second generation potent and selective FLT3 inhibitor
Authors: Ruwanthi Gunawardane, Allison Rooks, Alan Dao, Daniel Brigham, Jill Ricono, Patrick Zarrinkar, Shripad Bhagwat, Barbara Belli, Wendell Wierenga, Robert Armstrong
Journal: Cancer Research (2010)

Abstract Fms-like tyrosine kinase 3 (FLT3) is thought to be a major driver in the pathogenesis of acute myeloid leukemia (AML). FLT3-activating mutations are found in ∼ 30% of AML patients and are associated with poor outcome in this patient population. AC220 is a small molecule kinase inhibitor with potent and selective FLT3 inhibitory activity. Here we characterize the effect of AC220 on FLT3 autophosphorylation, activation of downstream signaling pathways (STAT5, ERK and AKT), cell cycle distribution, and apoptosis endpoints in multiple leukemia cell lines expressing either wild type FLT3 (FLT3-WT, SEM-K2 cells (FLT3-WT overexpression) and RS4;11 cells (FLT3-WT)) and/or ITD-mutated FLT3 (FLT3-ITD, MV4-11 (FLT3-ITD), MOLM-14 (FLT3-ITD/FLT3-WT)). Across each of these parameters we also compare the effects of AC220 to those of other known FLT3 inhibitors including, sorafenib, sunitinib, lestaurtinib, and midostaurin. AC220 inhibited FLT3 autophosphorylation in both FLT3-WT and FLT3-ITD cells with roughly equal potency, while other FLT3 inhibitors showed differential pFLT3 inhibition across several cell lines. Although AC220-mediated inhibition of FLT3 autophosphorylation was observed in all cell lines, subsequent cell death was only detected in the cell lines with activated FLT3. This contrasts with other FLT3 inhibitors, where potent inhibition of cell proliferation in the non-FLT3 activated RS4;11 cells was observed, highlighting the lack of FLT3 selectivity of these compounds. Consistent with FLT3 inhibition, AC220 also inhibited constitutively activated STAT5, ERK and AKT in these cell lines, suggesting that one or more of these pathways play a role in FLT3-mediated cell growth and survival. Furthermore, the inhibition of these downstream markers correlated with the inhibition of FLT3 across each of the FLT3 inhibitors tested. Lastly, in an MV4-11 murine xenograft model, AC220 administration resulted in the reduction of phosphorylated FLT3 and downstream signaling molecules concomitant with tumor reduction. Together, these data suggest that selective FLT3 inhibition is sufficient to inhibit the growth and induce cell death of FLT3-driven leukemia cells. AC220 is currently being evaluated in a phase II clinical trials in relapsed or refractory AML patients. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 3619.
OUTCOMES AND READMISSION RATE WITHIN 30 DAYS AND 6 MONTHS AFTER ACUTE MYOCARDIAL INFARCTION IN CHINA: DATA FROM THE CHINA ACUTE MYOCARDIAL INFARCTION REGISTRY
Authors: Haiyan Xu, Stephen D. Wiviott, Marc S. Sabatine, Xiaojin Gao, Jingang Yang, Yang Wang, Yuejin Yang, Fuwai Hospital
Journal: Journal of the American College of Cardiology (2016)
NUCLEAR MEDICINE PICTURE ARCHIVING AND COMMUNICATION SYSTEM (PACS).
Authors: P. H. Brown, G. T. Krishnamurthy, J. V. Glowniak, S. Prasad, E. Doo, J. Walroth, S. Gilbert, M. Eklem
Journal: Clinical Nuclear Medicine (1988)

Brown, P. H.; Krishnamurthy, G. T.; Glowniak, J. V.; Prasad, S.; Doo, E.; Walroth, J.; Gilbert, S.; Eklem, M. Author Information
AB0732 Gendered Issues about Spondyloarthritis. Another CASE Yentl's Syndrome?
Authors: V. Jovani, M. Blasco, M.T. Ruiz-Cantero, E. Pascual
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Different presentation of clinic manifestations (signs and symptoms) of Spondyloarthritis (SpA) in women and, its variant in men, Ankylosing Spondylitis (AS), and the lack of specificity of the presentation in women, may result in a lower diagnostic suspicion and a diagnostic error in them, as well as less diagnostic and therapeutic effort prior to specialized health. <h3>Objectives</h3> To reinforce the differences in signs/symptoms and the diversity of erroneous diagnostics in patients of both sexes finally diagnosed of AS/SpA, together with quantifying the delay in the diagnoses with AS/SpA in both sexes. <h3>Methods</h3> Retrospective observational design, comparing two groups of patients: 51 men and 28 women diagnosed with Ankylosing Spondylitis and Spondyloarthitis, respectively, at Rheumatology Section, Hospital General Universitario de Alicante (2012-2014). Source: Semi-structured interview on clinical stages of care: symptoms and signs perceived by the patients, conducting clinical history, physical examination and laboratory tests, health care itineraries prior to diagnosis, types of delays, and previous alternative/erroneous diagnostics. A descriptive analysis. <h3>Results</h3> SpA has been confused with 30 alternative or misdiagnosis in 74.5% of men and 78.6% of women. With recent ASAS criteria, after 2009, more women (21.4%) than men (9.43%) are diagnosed of AS. 26 different types of symptoms are referred by patients with AS (21 in women and 20 in women), 15 of them common in both sexes. Men take an average of 16 months for asking for health care after the onset of symptoms, women take 12 months. Meanwhile, the average of delay in AS diagnosis is 6.8 years in men and 6.1 years in women. <h3>Conclusions</h3> Not all symptoms are referred with same frequency in both sexes. It should be studied if men report more specific symptoms and women more non-specific. Also, if men describe both signs and symptoms while women only symptoms. In addition, if women report almost-wrong diagnoses that may help to address other types of diagnostic suspicion. Despite the existing knowledge of Spa/AS the non-diagnostic suspicion and the confusiόn with wrong diagnosis underlie the delay in healthcare. ASAS criteria reduce the differences in SpA diagnosis in both sexes. Patients report complex health care pathways, so, it is necessary to check if so many alternative/erroneous diagnosis to SpA/AS are related with the frequency of visits to primary and specialized health system. <h3>References</h3> van der Horst-Bruinsma IE et al. Ann Rheum Dis 2013;62:789-90. Lee W et al. Ann Rheum Dis 2007;66:633-638. Slobodin D et al. Clin Rheumatol 2011;30:1075-80. Roussou E. Rheumatol Int 2012;32:1597-604. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.5563
Deep Venous Thrombosis and Pulmonary Embolism Detected by FDG PET/CT in a Patient With Bacteremia
Authors: Anne Lerberg Nielsen, Anders Thomassen, Søren Hess, Abass Alavi, Poul Flemming Høilund-Carlsen
Journal: Clinical Nuclear Medicine (2013)

We report incidental FDG PET/CT findings of deep venous thrombosis and pulmonary embolism in a patient with bacteremia. In this patient, diagnosis of thromboembolism was not considered until FDG PET/CT imaging was performed, and the findings prompted immediate anticoagulant therapy. The role of FDG PET/CT in venous thromboembolism is not yet well established, but the potential benefit must be kept in mind when interpreting FDG PET/CT images regardless of the underlying disease.
Follicular Lymphoma Showing Avid Uptake on 68Ga PSMA-HBED-CC PET/CT
Authors: Gowri L. Kanthan, Luke Coyle, Andrew Kneebone, Geoffrey Paul Schembri, Edward Hsiao
Journal: Clinical Nuclear Medicine (2016)

68Ga prostate-specific membrane antigen (PSMA) PET/CT is a new imaging technique that is significantly more sensitive to prostate cancer lesions than other conventional imaging modalities. Various other benign and malignant neoplasms may also express PSMA and show uptake on PSMA PET/CT scan. We report a case of 66-year-old man who had a PSMA PET/CT scan for restaging of prostate carcinoma. A PSMA-avid left femoral lymph node was identified. Subsequent biopsy confirmed the diagnosis of follicular lymphoma. It is important to be aware of this possibility to avoid scan misinterpretation. Biopsy of any atypical or clinically unexpected lesions should be considered.
1365 METABOLIC ALTERATIONS OF LIPID KINETICS IN NAFLD PATIENTS AND THEIR CONTRIBUTION TO LIVER DAMAGE
Authors: C. Rosso, E. Vanni, L. Mezzabotta, R. Gambino, S. Carenzi, F. Saba, E. Buzzigoli, M. Gaggini, G.P. Caviglia, M. Cassader, A. Smedile, M. Rizzetto, A. Gastaldelli, E. Bugianesi
Journal: Journal of Hepatology (2013)
CyberKnife Radiosurgery Planning of a Secreting Pituitary Adenoma Performed With 68Ga DOTATATE PET and MRI
Authors: Andrea d’Amico, Małgorzata Stąpór-Fudzińska, Rafał Tarnawski
Journal: Clinical Nuclear Medicine (2014)

The images of a patient with acromegaly, who previously underwent operation for pituitary adenoma, were obtained. The MRI scan showed a mass in the right cavernous sinus, with biochemical test results positive for the presence of a hormonally active adenoma. The patient was scheduled for CyberKnife radiotherapy. Radiotherapy planning was carried out using MRI and PET/CT scan with somatostatin analog 68Ga DOTATATE. The latter showed radiopharmaceutical uptake on the adenomatous residual mass. Contours were drawn on MRI and PET images and were summed up to devise the radiotherapy plan. The patient was treated with a total dose of 24 Gy.
SAT0519 Facilitators and Barriers to Adherence to Urate-Lowering Therapy in African-Americans with Gout: A Qualitative Study
Authors: J.A. Singh
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> African-Americans share a disproportionate burden of gout compared to Caucasians, with a higher prevalence, lower likelihood of treatment with ULT including allopurinol, higher rates of non-adherence with ULT and higher baseline serum urate and lower odds of achieving target serum urate &lt;6 mg/dl. To our knowledge, there are no studies investigating the reasons for poor medication adherence in African-Americans with gout. <h3>Objectives</h3> To examine the facilitators and barriers to adherence to urate-lowering therapy (ULT) in African-Americans with gout. <h3>Methods</h3> Nine nominal groups lasting 1-1.5 hour each were conducted in African-Americans with gout, six with low ULT and three with high ULT adherence (medication possession ratios of &lt;0.80 or ≥0.80, respectively). Patients presented, discussed, combined and rank ordered their concerns. A qualitative analysis was performed. <h3>Results</h3> 43 patients with mean age 63.9 years (standard deviation, 9.9), 67% men, participated in nine nominal groups (seven in men, two in women): African-American men (n=30); African-American women (n=13). The main facilitators to ULT adherence (three groups) were the recognition of the need to take ULT regularly to prevent gout flares, prevent pain from becoming chronic/severe and to have less dietary restriction; the lack of side effects from ULT; trust in physicians; and avoiding the need to seek emergent/urgent care for flares. Patients achieved high ULT adherence by organizing their pills using the pillbox and the incorporation of ULT intake into their routine to prevent forgetting. The main barriers to optimal ULT adherence were (six groups): doubts about effectiveness of ULT, concerns about cost and side effects, concomitant medications, forgetfulness, refilling the prescriptions on time, pill size and difficulty in swallowing, competing priorities, patient preference for alternative medicines (i.e. cherry juice) and frequent travel. <h3>Conclusions</h3> Identification of facilitators and barriers to high ULT adherence in African-Americans with gout in this study lays the foundation for designing interventions to improve ULT adherence in racial minorities. <h3>Acknowledgements</h3> This material is the result of work supported by a grant from the Division of Rheumatology at the University of Alabama at Birmingham and the resources and use of facilities at the Birmingham VA Medical Center, Alabama, USA. J.A.S. is also supported by grants from the Agency for Health Quality and Research Center for Education and Research on Therapeutics (CERTs), National Institute of Arthritis, Musculoskeletal and Skin Diseases (NIAMS), National Institute of Aging (NIA) and National Cancer Institute (NCI). <h3>Disclosure of Interest</h3> J. Singh Grant/research support: Takeda, savient, Consultant for: Takeda, savient, regeneron, allergan <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.1148